LL-37 dosage
LL-37 is the active fragment of human cathelicidin, an antimicrobial peptide your own cells make. The only human trial is topical: 0.5 to 1.6 mg/mL applied twice a week to leg ulcers sped healing, and 3.2 mg/mL did not. No human has been dosed by injection in a study. Community use is 100 to 200 mcg subcutaneously, once a day, 5 days a week, for 2 to 4 weeks. It is a potent peptide, so people run it short.
Basis: clinical trial (Gronberg et al. 2014, Wound Repair Regen, 34 patients with venous leg ulcers, randomized, placebo-controlled, 4 weeks). healing rate about 6-fold higher at 0.5 mg/mL; 3.2 mg/mL no better than placebo; no safety concerns
- How often
- once daily, 5 days a week (community); twice weekly topical (trial)
- When
- any time; near a wound site for local use
- How long
- 2 to 4 weeks on, 2 weeks off
- Route
- subcutaneous (community) or topical on wounds (trial)
- Storage
- lyophilized: freezer; reconstituted: fridge, use within 2 to 4 weeks (commonly reported); it degrades faster than most peptides
Dose ranges by source
| Range | Per | Basis | Note |
|---|---|---|---|
| 0.5 mg/mL to 1.6 mg/mL topical, twice weekly | application | clinical trial (Gronberg et al. 2014, Wound Repair Regen, 34 patients with venous leg ulcers, randomized, placebo-controlled, 4 weeks) | healing rate about 6-fold higher at 0.5 mg/mL; 3.2 mg/mL no better than placebo; no safety concerns |
| 100 mcg to 200 mcg per injection | injection | commonly reported | once daily, 5 days a week, 2 to 4 weeks; no established human subcutaneous dose |
LL-37 dose to units chart
5 mg vial + 5 mL bacteriostatic water = 1 mg/mL (10 mcg per unit on a U-100 insulin syringe). 5 mg + 5 mL = 1 mg/mL, so 100 mcg = 0.1 mL = 10 units and 200 mcg = 20 units. For a topical mix in the trial range, 5 mg in 5 mL is already 1 mg/mL.
| Dose | mL | Units (U-100) | Doses per vial |
|---|---|---|---|
| 1 mcg | 0.0005 | 0.05 | 10000 |
| 1 mcg | 0.001 | 0.1 | 5000 |
| 2 mcg | 0.0016 | 0.16 | 3125 |
| 2 mcg | 0.002 | 0.2 | 2500 |
Different vial or water? Full 5 mg + 5 mL table or set your own numbers below.
Commonly stacked with
- KPV 200 mcg to 500 mcg per injection
Side effects
- injection site pain and redness (it is cytotoxic at high concentration)
- flu-like fatigue (reported)
- headache (reported)
LL-37 dosage questions
LL-37 peptide dosage?
No human injection dose exists. Community use is 100 to 200 mcg subcutaneously once a day, 5 days a week, for 2 to 4 weeks. The human trial used it on the skin at 0.5 to 1.6 mg/mL twice a week, and the higher 3.2 mg/mL dose did worse than the low ones.
How many units of LL-37 is 100 mcg?
With 5 mg in 5 mL (1 mg/mL) 100 mcg is 10 units. With 2 mL of water it is 4 units, which is hard to read, so use the full 5 mL.
Can you inject LL-37 near a wound?
People do, subcutaneously a few centimeters from the site, copying the topical trial logic. The trial itself applied it to the wound surface. Do not inject into infected or broken skin.
How long should an LL-37 cycle be?
2 to 4 weeks, then at least 2 weeks off. The trial ran 4 weeks. Longer continuous use has no data and the peptide can irritate tissue.
Sources
- Gronberg A et al., Wound Repair Regen 2014, Treatment with LL-37 in hard-to-heal venous leg ulcers: a randomized, placebo-controlled clinical trial (PubMed 25041740)
- Peptide Protocol Wiki, LL-37 dosing (community subcutaneous ranges)
Brands we recommend for LL-37. We are independent and have no affiliation with any brand: no affiliate links, no referral codes, no paid placements. These are the suppliers whose testing and certificates hold up when we check them.
- Licensed Peptides two accredited labs on every lot, certificates public, card and Apple Pay checkout
- Core Peptides long track record, public certificates, wide catalog
- Ascension Peptides public third-party testing, clear pricing
This page is an educational summary of published labels, trials and commonly reported use. It is not medical advice and does not replace a clinician.